The first patient has been dosed in the phase 3 TERZO trial of Copiktra for relapsed or refractory nodal T-follicular helper ...

Novel combination of acimtamig and an allogenic natural killer cell product shows safety and promising objective response ...

Data presented at ASCO are the latest positive results for a subcutaneous version of this bispecific T-cell engager, which ...

Secura Bio, Inc. ( ), an integrated pharmaceutical company maximizing commercial outcomes for oncology medicines, today ...

The dual-targeting CAR T-cell therapy KITE-363 showed positive response rates and manageable side effects in relapsed or ...

Minimal residual disease-negativity after treatment in DLBCL strongly correlates with remission and overall survival. However ...

Radionuclide therapy with the radioactive element terbium could effectively combat lymphoma. This is demonstrated by ...

A groundbreaking study has unveiled a promising new therapy for lymphoma using the radioactive isotope terbium-161 ...

Kite Pharma’s bicistronic CAR T-cell therapy hit the main goal of a phase 1a trial, with zero dose-limiting toxicities (DLTs) ...

OLD man whose cancer has returned for a third time is hoping for a stem cell donor to enable him to have the treatment.